CAS: 7535-56-0; Boc-Phe-Onp

相似化合物

16159-70-9 2578-84-9 2578-85-0

上下游产品

CAS号100-02-7 对硝基苯酚 | CAS号13734-34-4 B°C-L-苯丙氨酸 | CAS号107960-06-5 (4-nitrophenyl)... | CAS号1070-19-5 Carbonazidic ac... | CAS号2577-90-4 (S)-2-氨基-3-苯基丙酸甲酯 | CAS号16214-37-2 N-Carbonyl-phen... | CAS号75-65-0 叔丁醇 | CAS号13303-10-1 (4-硝基苯基)碳酸叔丁酯 | CAS号16480-57-2 sodium,(2S)-2-a... | CAS号33014-68-5 叔丁氧羰基-L-苯丙酰-L-亮氨酸 | CAS号58569-55-4 蛋氨酸脑啡肽 | CAS号58822-25-6 [Leu5]-脑啡肽 | CAS号23420-32-8 N-[(1,1-二甲基乙氧基)... | CAS号100-02-7 对硝基苯酚 | CAS号51987-73-6 N-B°C-L-苯丙氨酸甲酯 | CAS号19901-50-9 methyl 2-[(2-me... | CAS号98760-08-8 (2R,3S)-1,2-环氧-... | CAS号165727-45-7 (3S)-3-(叔丁氧羰基)氨... | CAS号13734-34-4 B°C-L-苯丙氨酸

📜N-重氮基氨基甲酸叔-丁基酯置于n,N'-二环己基碳二亚胺体系中,用 乙酸乙酯 作为反应溶剂,化学反应生成 Boc-L-苯胺-4-硝基苯酯
参考文献:Wuensch,E. Et Al.,Chemische Berichte,1964,Vol. 97,P. 1819-1828
标题:Wuensch,E. Et Al.,Chemische Berichte,1964,Vol. 97,P. 1819-1828

专利信息

专利号:US-4704450-A
优先权日:1983-02-21
标 题 :Synthesis of hpGRF(Somatocrinin) in liquid phase and intermediate peptides
发明人：DIAZ JOSEPH; DEMARNE HENRI; RONCUCCI ROMEO; SCHMELCK PAUL-HENRY
权利人:SANOFI SA
摘要:The invention relates to synthesis of hpGRF (Somatocrinin) in liquid phase and to intermediate peptides, comprising: coupling, one after the other and in the order of the sequence of the GRF, the fragments in which: (a) the side acid functions of the aspartic and glutamic acids and the side amine function of the lysine are protected by protector groups stable in the conditions of deprotection of the group Boc, (b) the guanidine function of the arginine is protected by protonation, and (c) the N-terminal amino acid is protected on the amine by the Boc group; selectively eliminating the group Boc from the N-terminal amine of the peptide in phase of elongation by hydrolysis with trifluoroacetic acid, said coupling being effected in an aprotic polar solvent and eliminating, at the end of sequence, all the protector groups by hydrolysis with the aid of a 0.1 to 1M solution of methanesulfonic or trifluoromethanesulfonic acid in trifluoroacetic acid.

专利号:US-4581168-A
优先权日:1983-02-21
标题:Synthesis of hpGRF (Somatocrinin) in liquid phase and intermediate peptides
发明人：DIAZ JOSEPH; DEMARNE HENRI; RONCUCCI ROMEO; SCHMELCK PAUL-HENRY
权利人:SANOFI SA
摘要:The invention relates to synthesis of hpGRF (Somatocrinin) in liquid phase and to intermediate peptides, comprising:--coupling, one after the other and in the order of the sequence of the GRF, the fragments in which: (a) the side acid functions of the aspartic and glutamic acids and the side amine function of the lysine are protected by protector groups stable in the conditions of deprotection of the group Boc, (b) the guanidine function of the arginine is protected by protonation, and (c) the N-terminal amino acid is protected on the amine by the Boc group;--selectively eliminating the group Boc from the N-terminal amine of the peptide in phase of elongation by hydrolysis with trifluoroacetic acid, said coupling being effected in an aprotic polar solvent and--eliminating, at the end of sequence, all the protector groups by hydrolysis with the aid of a 0.1 to 1M solution of methanesulfonic or trifluoromethanesulfonic acid in trifluoroacetic acid.

专利号:US-4797469-A
优先权日:1984-07-10
标 题:Synthesis of hGRF (Somatocrinin) in liquid phase and intermediate peptides
发明人：DIAZ JOSEPH; DEMARNE HENRI; RONCUCCI ROMEO; SCHMELCK PAUL-HENRY
权利人:SANOFI SA
摘要:A process for the synthesis, in liquid phase and by fragments, of hGRF 1-44 and hGRF 1-40. This process consists in coupling, one after the other and in the order of the sequence of the GRF, (1) on the one hand, the following fragments: -H-Ala-Arg-Ala-Arg-Leu-NH2 called Fragment A hGRF (40-44) or - alaninamide (40) -H-Gln-Glu-Arg-Gly-OH called Fragment B'1 hGRF (36-39) -H-Glu-Ser-Asn-OH called Fragment B'2 hGRF (33-35) -H-Ser-Arg-Gln-Gln-Gly-OH called Fragment C hGRF (28-32) -H-Leu-Gln-Asp-Ile-Met-OH called Fragment D' hGRF (23-27) -H-Arg-Lys-Leu-OH called Fragment E'1 hGRF (20-22) - to obtain the peptide K1 [(hGRF (20-44)] on the corresponding peptide having the sequence (20-40) and (2) on the other hand, the following fragments: -H-Gln-Leu-Ser-Ala called Fragment F1 hGRF (16-19) -H-Tyr-Arg-Lys-Val-Leu-Gly OH called Fragment G1 hGRF (10-15) -H-Ile-Phe-Thr-Asn-Ser-OH called Fragment H1 hGRF (5-9) - to obtain the peptide J [hGRF (5-19)] and thereafter to couple together the peptides J and K1 in order to form the peptide having the sequence hGRF (5-44) or hGRF (5-40) and finally to couple the resulting peptide with the peptide H-Tyr-Ala-Asp-Ala-OH, called fragment I hGRF (1-4).

专利号:US-4891430-A
优先权日:1984-12-04
标 题:Process for synthesizing active esters of carboxylic acids, new alpha-halogenated carbonates which are useful for this synthesis and the method of producing them
发明人：BARCELO GERARD; CASTRO BERTRAND; JAOUADI MAHMOUD; MARTINEZ JEAN; SENET JEAN-PIERRE; SENNYEY GERARD
权利人:INT DES POUDRES ET EXPLOSIFS S
摘要:The invention relates to a new process for preparing active esters or carboyxlic acids, which consists in reacting a carboxylic acid, in the presence of an agent for binding hydrohalic acid, with a carbonate of formula: ##STR1## in which R 1 denotes either a radical of formula ##STR2## in which R 3 and R 4 , which may be identical or different, are not hydrogen atoms and denote organic radicals which may be substituted or unsubstituted and saturated or unsaturated, and may or may not be bound to a polymer, and which can be joined together to form a hetero-cyclic system with the nitrogen, atom, n or a substituted or unsubstituted aryl radical which may or may not be bound to a polymer, n R 2 denotes a hydrogen atom, an aliphatic or cycloaliphatic radical which may be substituted or unsubstituted and saturated or unsaturated, or a substituted or unsubstituted aromatic radical, n and X denotes a halogen atom. n This process is especially useful for the synthesis of active esters of N-protected amino acids. The invention also relates to the new carbonates described above and the method of producing them, which consists in reacting an alpha-halogenated chloroformate of formula: n n R.sup.2 --CHX--O--COCl n n with an alcohol of formula R 1 OH in an inert solvent medium in the presence of an organic or inorganic base.

专利号:US-2004110228-A1
优先权日:2002-04-01
标 题:Combinatorial organic synthesis of unique biologically active compounds
发明人：MCALPINE SHELLI R; TAYLOR RACHEL E; BOLLA MEGAN L; SEGALL ANCA M
摘要:The invention provides a method for making a combinatorial library of cyclic compounds, such as Holliday junction-trapping compounds, comprising the steps of (a) obtaining a plurality of trimers according to the generic structure X 1- X 2- X 3 , wherein X 1 , X 2 and X 3 can be independently any naturally or nonnaturally occurring amino acids or peptidomimetics thereof; (b) optionally coupling a spacer S to the trimer at either end; (c) cyclizing two trimers or trimer-spacer conjugates in a head-to-tail orientation; thereby obtaining a combinatorial library of compounds, wherein the library does not include an unmodifed or naturally occurring Holliday Junction-trapping compounds. The invention additionally provides methods macrocyclic compounds that are synergimycin derivatives.

专利号:US-3996268-A
优先权日:1974-09-03
标题:Cross-linking reagent for insulin synthesis
发明人：CARPENTER FREDERICK H; BUSSE WOLF-DIETER
权利人:UNIV CALIFORNIA
摘要:Carbonyl-bis (L-methionine p-nitrophenyl ester) and its analogues are useful reagents for the intermolecular cross-linking of two chain peptide molecules such as occur in the hormone insulin. The cross-linking occurs across amino groups at preferred positions in the two peptide chains to fix the relative spacial position of the peptide chains and permit the oxidative formation of necessary disulfide bridges between the chains in high yields. The reagent is then removed from the linked chains to yield the insulin molecule. A method for preparation of the reagent is disclosed. Further, a procedure is disclosed by which the cross-linking reagent is used to specifically block certain amino groups on insulin to yield a cross-linked insulin which in turn is used to prepare isotopically labeled insulin and insulin analogues.